Legacy Pharmaceutical Losartan Tablets Recall: Impurity Risk
Legacy Pharmaceutical Packaging LLC recalls Losartan Potassium Tablets (50mg) due to detected impurity NMBA. Affected lots: 180190, 180191 (exp 10/2020) and 181597 (exp 02/2021).
Recall notice
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected.
Contact the company
What happened, in plain English
Legacy Pharmaceutical Packaging LLC is recalling Losartan Potassium Tablets (50mg) because they contain an impurity called NMBA. This impurity could pose a health risk to people taking the medication. Read more at govinfonow.com/recall/39135-legacy-pharmaceutical-losartan-tablets-recall-impurity-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/39135-legacy-pharmaceutical-losartan-tablets-recall-impurity-risk · Updated October 5, 2026 · FDA enforcement record: FDA #D-1075-2019
Cite this page
“Legacy Pharmaceutical Losartan Tablets Recall: Impurity Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/39135-legacy-pharmaceutical-losartan-tablets-recall-impurity-risk. Based on FDA recall #D-1075-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1075-2019%22&limit=1).
Why it’s dangerous
The recall is due to the presence of an impurity called N-Methylnitrosobutyric acid (NMBA) in the medication. While the exact health risk isn't specified in the recall, impurities in medications can sometimes cause adverse reactions.
Who’s affected
People who have prescription Losartan Potassium Tablets (50mg) from Legacy Pharmaceutical Packaging LLC. Those with the specific lots mentioned are most at risk.
How to tell if you have this one
Check your prescription bottle for the product name 'Losartan Potassium Tablets, USP, 50 mg, 30 tablets'. Look for the lot numbers 180190, 180191 (expiring 10/2020) or 181597 (expiring 02/2021).
- Brand
Legacy Pharmaceutical Packaging LLC- Category
Drug
What to do — step by step
Check Product Details
Identify your bottle by checking the product name and lot numbers listed above.
Where it went and when
Where it was distributed
Distributed in 3 states.
FDA distribution: “AZ, IN, TN” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Arizona, Indiana, Tennessee.
Recall timeline
FDA terminated this recall 4.6 years after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1075-2019 (March 1, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1075-2019 to see it in context.
- Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.